Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15719386 | 0.93 | SLC6A2 (0.45) | PDE2APPARGPPARASLC6A2SLC6A4 | |
| SCHEMBL15719996 | 0.87 | PDE2A (0.42) | PDE2APPARGPPARATRPV1SLC6A2 | |
| SCHEMBL5653707 | 0.86 | SMYD3 (0.44) | SMYD3AAK1SLC6A2SLC6A4 | |
| SCHEMBL16394313 | 0.86 | AAK1 (0.45) | SMYD3AAK1 | |
| SCHEMBL4116055 | 0.85 | SMYD3 (0.53) | SMYD3 | |
| SCHEMBL5652485 | 0.82 | SLC6A3 (0.43) | PPARGPPARASMYD3AAK1SLC6A2 | |
| SCHEMBL382374 | 0.82 | HPGD (0.44) | SMYD3SLC6A2SLC6A4 | |
| SCHEMBL4715527 | 0.79 | SMYD3 (0.46) | SMYD3SLC6A2SLC6A4 | |
| SCHEMBL4715530 | 0.79 | SMYD3 (0.46) | SMYD3SLC6A2SLC6A4 | |
| SCHEMBL454274 | 0.77 | HTR2C (0.49) | PDE2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| EP-2234973-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | PDE2A 4034/4885PPARG 4152/4885PPARA 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.